untitled

Size: px
Start display at page:

Download "untitled"

Transcription

1 Infectious Agents Surveillance Report (IASR) 3, 4, JANIS 5, 6, 8, 9, KPC 11, : 12, 13, 14, EV-D68 15 Vol. 40 No Vol.40 No. 2 No.468 ISSN Tel , 1,, 2 :,,, CRE CRE, - Escherichia coli Klebsiella pneumoniae CRE,,,,,,,, NESID: CRE kekkaku-kansenshou11/ html CRE ,600, , ,,,, , , Enterobacter cloacae, Klebsiella aerogenes 2017, K. pneumoniae, E. coli, 2017 K. aerogenes, 3 : CRE CPE-, CPE, CRE 8 CPE,,, CRE CPE, , CRE, 3 2, , n 1, , ,400 1,200 1, (n=314) (n=1,669) (n=1,573) (n=1,660) (n=2,074) ,

2 218 Vol. 40 No , IMP, 1 NDM, KPC, OXA ,669, ,573, IASR , : , ,074 Klebsiella aerogenes Enterobacter cloacae Escherichia coli, Klebsiella pneumoniae , , IMP , CRE IMP IASR 39: , 2018, 6, 2018 KPC 11 NDM 12, AMR, CRE, NESID, 4 JANIS : JANIS, 2,000, NESID,, CRE ,000 JANIS CRE, NESID, CRE CRE NESID, K. aerogenes JANIS : CRE AMR,,,,, WHO, OIE, 3 FAO AMR NAP ,,, JANIS, JVARM,, ; go.jp/content/ / pdf, AMR : 2015 WHO AMR GAP, 2016 NAP go.jp/f ile/06-seisakujouhou kenkoukyoku/ pdfNAP, AMR,,,, WHO AMR AMR 2017 NAP AMR JANIS E. coli K. pneumoniae 0.2 NAP 2017 K. pneumoniae 0.4, NESID 2018,,

3 Vol. 40 No ,, , CRE,,,,, , ,, 13 PCR, -,, IMP, NDM, KPC, OXA-48,, VIM, GES, IMI, KHM, SMB, 2018, Carba NP test CIM,,, NDM, KPC, OXA-48 18, 2, 1, 13, 12, 1, 165, 1 PCR, 2 PCR, , CRE , , , , , , , ,, 100, 1, CRE 2017, 1,.

4 420 Vol. 40 No NESID,, *,, CRE, NESID *,, *,,,, /, * NESID ID ID,,, 1IASR 39: , 2018,, NESID ID,,, Infectious Disease Surveil , carbapenem-resistant Enterobacteriaceae: CRE National Epidemiological Surveillance of Infectious Diseases: NESID 5,

5 Vol. 40 No * lance Center: IDSC Antimicrobial Resistance Research Center: AMRRC, , CRE,, CRE,,,,,, IDSC,, AMRRC,, 8 NESID, , NESID 2, , 1,154 56, NESID ID , NESID ID,, 10,000 8,000 6,000 4,000 2,000 JANIS JANIS,, CRE, 2014, 2015 JANIS NESID,,,, 30, JANIS CRE , JANIS CRE, ,254 CRE, ,827, ,572 JANIS janis.mhlw.go.jp/hospitallist/index.html, CRE CRE, 1 0 8, , (%) 7,827 7, CRE

6 622 Vol. 40 No Proteus mirabilis, 1.0% Enterobacter asburiae, 0.8% Klebsiella oxytoca, 2.0% Enterobacter sp., 2.8% Citrobacter freundii, 2.9% Serratia marcescens, 4.3% Escherichia coli, 7.0% Klebsiella pneumoniae, 8.9% 2. CRE, 4.5% Klebsiella aerogenes, 35.2% Enterobacter cloacae, 30.5% 3. CRE -2017, , 0.25, , , 0.08, 0.53 Shapiro- Wilk p=0.33, 90 4,, JANIS, CRE, CRE, , , , ,, CRE ,, , , 2017 CRE, 2 Klebsiella aerogenes 35.2, Enterobacter cloacae , Klebsiella pneumoniae 8.9, Escherichia coli 7.0, Serratia marcescens 4.3, JANIS, JANIS,, html, CRE 2016, 3,,,,, CRE, JANIS 11, 3 CRE,, 75, 90,, CPE, carbapenemase-producing Enterobacteriaceae; CPE, -, CPE, 1, CPE IMP, IMP IMP-6,, minimum inhibitory concentration ; MIC 1 g/ml MIC 0.251g/mL,, CPE, Clinical and Laboratory Standards Institute CLSI 2 Carba NP test, modif ied Carbapenem Inactivation Method mcim, -

7 Vol. 40 No , Carba NP test, ph, mcim,,, Escherichia coli ATCC 25922, Carba NP test,,,, KPC, -- SMA-,,,, polymerase chain reaction PCR,, PCR,,, - IMP, VIM, KPC, NDM, OXA, GES, multiplex PCR -c, d,,,,,, ESBL AmpC,,,,, CPE -a CPE -b,, -,,, CPE,, CPE,,

8 824 Vol. 40 No , 63: , CLSI, Performance Standards for Antimicrobial Susceptibility Testing, 27th Informational Supplement, 2017 CRE CRE, IPM MIC2g/mL CMZ MIC 64g/mL, MEPM MIC 2g/mL,, Klebsiella, Enterobacter, Serratia, Proteus,,,, CRE 5, ,581 1 Enterobacter cloacae 31.3, Klebsiella aerogenes 30.6, Klebsiella pneumoniae 11.7, Escherichia coli 9.8,, 32.4, 24.8, CRE,,, 31, 24, 21, 14, 3 CRE, CRE, empiric therapy CRE, CRE CRE,,,, 2,, -,, 29 MEPM MIC 2g/mL A 13 B 16, CPE A, -,, CPE,, 3 CRE CRE, CPE K. pneumoniae carbapenemase: KPC, 4 CRE, : CRE, MIC,, MIC1g/mL, MIC2g/mL 5, MIC8g/mL 6 pharmacokinetics/pharmacodynamics, 4 : Serratia Proteus, MIC 4, 7, 8 :

9 Vol. 40 No ,, 9 :,,, 4 CRE, 10,, CPE, 11,, CRE, CPE, , 10, , 3.4, 29, 26, CRE, CPE,, CRE, 2, 4 1IDWR, cre-idwrs/7393-cre html 2, 64: , Tamma PD, et al., Clin Infect Dis 64: , Morrill HJ, et al., Open Forum Infect Dis, doi: /of id/ofv050, Patel TS, et al., J Clin Microbiol 53: , Daikos GL, et al., Antimicrob Agents Chemother 58: , Liu Y-Y, et al., Lancet Infect Dis 16: , , , Tzouvelekis LS, et al., Clin Microbiol Infect 20: , Gutierrez-Gutierrez B, et al., Lancet Infect Dis 17: , 2017 CPE, 2020, CPE, CPE CPE,,,, -- IMP-1, -6, -34,,,,,, KPC CPE KPC Ambler class A --, 2001 Klebsiella pneumoniae,, KPC, IMP, KPC,, , KPC 37 NDM CPE NDM 2009, -

10 1026 Vol. 40 No , OXA-48 MEPM MEPM, 36kDa 2010, K. pneumoniae IPM MEPM bla OXA-48 family bla OXA-181 bla CTX- M-15 7, bla OXA-181 K. pneumoniae 2015, bla OXA NDM-1 NDM-1, 1, NDM-1 2, MIC bla NDM-1, 2013 NDM-3 3, 2013 NDM-5, 2014 NDM-5 K. pneumoniae , NDM 24 OXA-48-like CPE OXA - OXA-10,,,, OXA , 157 OXA-11 5, OXA-48-like 2001 K. pneumoniae 11978, 46 6, OXA, OXA-48 K. pneumoniae , bla OXA-181, bla OXA-181, ISEcp1, ISEcp1,, K. pneumoniae 11978, OmpK36,,, 1Chihara S, et al., Clin Infect Dis 52: , , 86, Tada T, et al., Antimicrob Agents Chemother 58: , Nakano R, et al., Antimicrob Agents Chemother 58: , Paterson D, et al., Clin Microbiol Rev 18: , Poirel L, et al., Antimicrob Agents Chemother 48: 15-22, Kayama S, et al., Antimicrob Agents Chemother 59: , 2015

11 Vol. 40 No KPC KPC Klebsiella pneumoniae carbapenemase carbapenem-resistant Enterobacteriaceae: CRE , 3 CRE,, , 3 KPC 3 A 2 80, 70, D KPC CRE,,, CRE, ,,, , 6, 16 3 C 20, 70, C , 5, A B 1 40, 60, D 2 70, 1 80, 1 80, A 3, B 1, C 13, D 3, C, 60 80, KPC CRE, FETP,, KPC CRE,,,,,,,,,,,,,,,,, ,,, KPC CRE KPC CRE, KPC 1 18,, FETP,,,,,, 2,,,, ,,,, AMR antimicrobial resistance :,

12 1228 Vol. 40 No :, 1, 2 2, 1NDM NDM-1 -- Acinetobacter pittii 1 OXA-48 Klebsiella pneumoniae OXA-48, OXA-48, NDM-1 A. pittii / PIPC/TAZ-, IPM MEPM MIC8g/mL, A. pittii sequence type ST220 bla NDM-1 26,940bp Acinetobacter sp. pndm-jn02 accession no. KM ,936bp/26,940bp bla OXA-213-family gene, A. pittii ST220 bla OXA-213-family accession no. CP , 12,265 bp ,264bp/12,265bp, AmpC bla ADC-25 NDM-1 2High Care Unit HCU 1 IMP-1 Enterobacter cloacae GES-24 Citrobacter freundii msupercarba, PIPC/TAZMIC, IPM MEPM MIC 1g/mL C. freundii Clinical and Laboratory Standards Institute mcim, MEPM,, inti1, aaca4, Klebsiella variicola bla GES , GES-24 A GES - extended-spectrum -lactamase, GES-4 GES-24 GES,, Kotay, P Escherichia coli 1 1, 4 National Institutes of Health Clinical Center 5, 1.4, 3.2, 12.5, ,,,, AMR,, AMR AMR 1Vergara-L ópez S, et al., Clin Microbiol Infect 19: E490-E498, White L, et al., J Hosp Infect 93: , Gomi R, et al., Antimicrob Agents Chemother, doi: /aac , Kotay S, et al., Appl Environ Microbiol, doi: /AEM , Weingarten RA, et al., MBio 9, doi: /mbio , 2018 bla GES-24

13 Vol. 40 No IMP, 1, KPC-2 Klebsiella pneumoniae ST11 2, KPC-2,,, KPC ,,,,, :,, AMR AMR,, -, CRE 3 CRE, 2020, WHO Global Sewage Surveillance Project GSSP 90 4 GSSP, AMR, AMR,,,

14 1430 Vol. 40 No , 6, AMR, AMR, AMR :,, 1Gomi R, et al., Antimicrob Agents Chemother 62 5: e , Sekizuka T, et al., msphere 3 5: e , Montezzi LF, et al., Int J Antimicrob Agents 45 2: , http:// Sewage-Surveillance-Project 5Nakayama T, et al., Infect Drug Resist: , Woerther PL, et al., J Travel Med. suppl_1: S29-S34, Review, 2017,, 4 NA,,,, , 3, PA 38 I38T/M/F, 1 III , ,, 1, 2,,,, 2017/18 3, ,, PA I38T 2 5 2, , , 1, 1 2 AH3N2 4, A/ /133/2018 A//135/2018, PA I38T, A//136/2018 A//134/2018, 2 PA I38T,,, 4, IC 50 50, PA I38T A//133/2018 A//135/2018, 2,, , 4 NA,,,, PA I38T, 4 2,000, 0.32, 4.1 6, 5 NA, 0 1.9, 2018/ , 250 NA 4, World Health Organization: WHO WHO NA,,

15 Vol. 40 No ,,,,,,, 3 2, D68 EV-D68 EV-D68,, 1Omoto S, et al., Sci Rep 8: 9633, Hayden FG, et al., N Engl J Med 379: , 2, 2018,, 3Takashita E, et al., Front Microbiol 9: 3026, EV-D lu-resist.html 1 : 16 5Takashita E, et al., Euro Surveill 24: pii= , : X , 6Aoki FY, et al., Antivir Ther 12: , , 28 : EV 5UTR-V 2 semi nested-rt PCR 1, EV-D68 PCR 2, PV L-20B RD-A 3 :,,, 16, EV RV, 2 PV 2 : 6 : X,,, 1 2,,,, 5,, 6, 9 EV-D68, , 5 34, , 5 1, 7,

16 1632 Vol. 40 No Clade : EV 5UTR-VP2 semi nested- GER/03-01/14-15_KP Fermon AF RT PCR 1 CAN14-344_KP455284, PV L-20B RD-A US/KY/ _KM A GER/NW/15-34/Germany/2013 KR , IRL_LOUTH_2014_49 KU GER/NW/15-34/Germany/2013_ KR SWE_013_2016_MH ITA/PV-38818/2016_MF : 6, GER_992165_MH SWE_042_2016_MH674157,, 7, TW-03464_2015_MH FRA/0906R002_KY EV- DE/BY/16-741/2016_KX NY234_16_KY D68 EV RV A194-OsakaC-JPN-2015_LC107892* 992 NY75_16_KX USA/FL/ _KX675261, PV SP AFP3601VI_KX NY188_16_KY : 15 DE/BW/16-674/2016_KX TW-03495_2015_MH : X, A250-OsakaC-JPN-2015_LC107900* L1882-Yamagata-2015_LC203572* , 3 SMC-15-Sendai881_KX789267* B 1758-Yamagata-2015_LC203575* 5 A241-OsakaC-JPN-2015_LC107898* A244-OsakaC-JPN-2015_LC107899*, 953 ITA/PV/ _MF : EV 5UTR-VP2 semi nested- United_Kingdom_2015_MH ITA/PV-37298/2016_MF EVD68VP EVD68VP11115 FRA_2009R0048_KY CUHK-PAE08/15_MG US/CA/ _2014_KP RT PCR 1, EV-D68 PCR 2, 1000 NY210_2014_KP NY120_2014_KP EV-D68 nested-rt PCR 3, PV L-20B RD-A 3, 2124-Yamagata-2005_AB ITA/26868/08_KC JPOC10-404_Osaka_City_2010_AB Yamagata-2010_AB C JPOC10-396_Osaka_City_2010_AB :VP1 :,, 369 bootstrap value > 950, 5,, 6 EV-D68 EV RV, PV, 2 2, , 2015 Clade B, bootstrap value 974/1,000, 2, 2018, , EV-D68, 2 3, 3 3,,, 15,, EV EV 5UTR-VP2 semi nested-rt PCR 1,, EV-D68 PCR 2, EV-D68 nested-rt PCR 3, EV-D68, 2015, 4,,, EV- D68,, i, ii PV EV PV,, 1, 27: , Wylie TN, et al., J Clin Microbiol 53 8: , , 91 3: , Chong PF, et al., Clin Infect Dis 66 5: , 2018

17 IASR Reporting situation of carbapenem-resistant Enterobacteriaceae in the Infectious Agent Surveillance System Effective utilization of carbapenem-resistant Enterobacteriaceae infection surveillance data Carbapenem-resistant Enterobacteriaceae: data from the Ministry of Health, Labour and Welfare s Japan Nosocomial Infections Surveillance (JANIS) system Microbiological testing methods for carbapenemase-producing Enterobacteriaceae in hospital settings Treatment of carbapenem-resistant Enterobacteriaceae infections Description of carbapenemase-producing Enterobacteriaceae from overseas Nosocomial infections of KPC-type carbapenem-resistant Enterobacteriaceae in the jurisdictional area of the Koriyama Local Health Center, Fukushima Prefecture, Carbapenemase-producing bacteria detected at a hospital sink: the importance of the hospital environment as a reservoir for antimicrobial resistant bacteria Monitoring antimicrobial resistance in the environment: contributions to a One Health approach Detection of influenza virus exhibiting resistance to the novel influenza antiviral drug baloxavir marboxil, Testing of patients with acute flaccid paralysis and case reports of patients detected with EV-D68, Osaka Prefecture, <THE TOPIC OF THIS MONTH> Carbapenem-resistant Enterobacteriaceae (CRE) Infection, Japan Carbapenem-resistant Enterobacteriaceae (CRE) infection is a broad term for infections caused by certain types of Enterobacteriaceae such as Escherichia coli and Klebsiella pneumoniae that are resistant to carbapenem and broad spectrum ß-lactam antibiotics. These antibiotics, such as meropenem, are most important for the treatment of Gram-negative bacterial infections. CRE mainly cause infections in patients with compromised immune systems, patients in their postoperative period, and patients who are administered antibiotics over a long period of time. Infection can result in infectious diseases, including respiratory infections, such as pneumonia, urinary tract infections, infections of surgical sites, skin, and soft tissues, medical device-associated infections (e.g. catheter-associated), sepsis, and meningitis, often causing hospital-acquired infections (HAIs). CRE can occasionally infect healthy individuals. In addition, there is often asymptomatic carriage of the bacteria such as in the digestive tract. National Epidemiological Surveillance of Infectious Diseases (NESID) Since September 19, 2014, CRE infection has been included in the list of category V infectious diseases (for the notification criteria, see: Additionally, in this surveillance system, only those who developed clinical manifestations are eligible for notification. While approximately 1,600 CRE infection patients were notified annually between 2015 and 2017, more than 2,000 cases were notified prior to December 25 (week 48) in 2018 (Fig. 1). Over a period of four years, approximately 80% of cases were found in patients aged 65 years or older. By prefecture, Tokyo, Kanagawa, Aichi, Osaka, and Fukuoka were the top five prefectures reporting the largest number of cases, accounting for 43% of all notifications. There were 35 prefectures whose number of annual notifications exceeded 10 in 2015, but this gradually increased to 38 in 2016, and 39 in 2017 and 2018 (through week 48 in 2018) (Fig. 2). Regarding the distribution of notifications by bacteria species, the top four species with the largest proportions were Enterobacter cloacae, Klebsiella aerogenes (N.B. the scientific name was changed in 2017), K. pneumoniae, and E. coli through 2018; the proportion of K. aerogenes began to increase from 2017, and it has since become the most notified bacteria species (Fig. 3 in p. 18). Infectious Agents Surveillance System Among CRE, carbapenemase-producing Enterobacteriaceae (CPE), which produce enzymes that break down carbapenem, are often resistant to antibiotics other than ß-lactam antibiotics, and bacteremia caused by CPE has been reported to have a poorer therapeutic prognosis than that caused by non-carbapenemase-producing CRE (see p. 24 of this issue). In addition, as the carbapenemase gene in CPE is located on mobile genetic elements, such as plasmids, in many cases, the drug-resistant property can be spread across bacterial species. Thus, distinguishing CPE from other CRE is considered to be necessary for both countermeasures against hospitalacquired infections and for therapy, and requires the implementation of carbapenemase gene examinations (see p. 22 of this issue). Based on the notice issued on March 28, 2017 by the Director of the Tuberculosis and Infectious Diseases Control Division, Health Service Bureau, Ministry of Health, Labour and Welfare, in the event of a CRE infection notification, prefectural and municipal public health institutes (and other relevant entities) are requested to conduct testing for the carbapenemase gene (resistance gene) in order to ascertain the situation in the area (see p. 19 of this issue). There are several known varieties of carbapenemase; the type frequently found in Japan is the IMP type, and the NDM, KPC, and OXA-48 types are spreading overseas. The types found overseas are often multidrug-resistant, frequently demonstrating resistance not only to carbapenem but also to other antibacterial drugs, and require particular attention in terms of infection control (IASR 35: , 2014). Of the strains registered in the Infectious Agents Surveillance System, at least one of the carbapenemase genes was detected in Figure 1. Age distribution of notified carbapenem-resistant Enterobacteriaceae infection cases by year, , Japan 2,200 Age group (year) 2, , n=no. notified cases 1, , ,144 1, , (n=314) (n=1,669) (n=1,573) (n=1,660) (n=2,074) Year 1 week 38-52, week 1-48, 2018 (National Epidemiological Surveillance of Infectious Diseases: as of 25 December 2018) No. notified cases Vol. 40 No. 2 (No. 468) February 2019 Infectious Agents Surveillance Report Figure 2. Yearly number of notified carbapenem-resistant Enterobacteriaceae infection cases by prefecture, , Japan No. of notified cases by prefecture ISSN National Institute of Infectious Diseases and Tuberculosis and Infectious Diseases Control Division, Ministry of Health, Labour and Welfare Year week 1-48, 2018 (National Epidemiological Surveillance of Infectious Diseases: as of 25 December 2018) Continued on page 18

18 IASR Vol. 40 No. 2 Feb THE TOPIC OF THIS MONTH-Continued Figure 3. Yearly number and proportion of notified carbapenem-resistant Enterobacteriaceae infection cases by bacterial species, , Japan Year No. notified 1 cases , , , ,074 Klebsiella aerogenes Enterobacter cloacae Escherichia coli Klebsiella pneumoniae difficulty in isolation Other or not described 1 week 38-52, week 1-48, No. notified cases differ from the sum of notifications by bacterial species because multiple strains were isolated from some cases. (National Epidemiological Surveillance of Infectious Diseases: as of 25 December 2018) 239 and 123 strains in 2017 and in the first half of 2018, respectively; the IMP type was detected in 227 and 111 strains in 2017, and during the first half of 2018, respectively, making it the most common type. In 2017, the proportion of CRE with IMP-type strain detection exhibited large regional differences in bacterial species and genetic types (see IASR 39: , 2018). On the other hand, six local governments reported cases of overseas-type carbapenemase gene-positive strains, and the majority were identified in patients who had no history of overseas travel. Moreover, in 2018, there was an outbreak caused by a KPC-type carbapenemase gene-positive strain (see p. 27 of this issue) and a report concerning contamination of the hospital environment by an NDM-type carbapenemase gene-positive strain (see p. 28 of this issue). Therefore, there is concern regarding the spread of overseas-type carbapenemase gene-positive strains into the community or hospital environments (see p. 25 of this issue). Since 2018, the Antimicrobial Resistance Research Center and the Infectious Disease Surveillance Center (both part of the National Institute of Infectious Diseases; NIID) have been jointly conducting a weekly teleconference on notified cases of CRE infection, sharing patient information from the NESID system along with the pathogen detection information, conducting risk assessment of notified cases, and contacting local governments as needed (see p. 20 of this issue). Japan Nosocomial Infections Surveillance (JANIS) system of the Ministry of Health, Labour and Welfare The Testing Division of JANIS continuously collects and collates all bacterial testing data obtained from over 2,000 participating medical institutions, representing the isolation status of major drug-resistant bacteria in Japan. Unlike the NESID system, no distinction is made between colonization and disease manifestation; data are compiled for bacteria isolated at the participating medical institutions that fulfill the laboratory criteria for notification under the Infectious Diseases Control Law. Although the number of patients with CRE continues to decrease, there were over 7,000 in As the number of patients with CRE isolation in the JANIS system is markedly higher than the number of patients included in the NESID system (limited to symptomatic cases), it is possible that there are many carriers of CRE. The proportions of CRE bacteria species reported by JANIS are consistent with those reported by NESID, and the increased proportion of K. aerogenes was also observed in the 2017 JANIS data (see p. 21 of this issue). Nippon AMR One Health Report (NAOR) Measures for responding to the antimicrobial resistance (AMR) problem, including CRE, require the One Health Approach, i.e., multi-sectoral cooperation and collaboration among the medical care, animal husbandry, and environmental sectors. On the global stage, organizations such as the World Health Organization (WHO), the World Organization for Animal Health (OIE), and the Food and Agriculture Organization (FAO) play a central role in this effort. The AMR National Action Plan (NAP) stipulates that comprehensive One Health Surveillance be implemented for drug-resistant bacteria isolated from humans, animals, food, and the environment. JANIS releases information on resistance rates for human-derived pathogenic bacteria isolated from participating medical institutions, and the Japanese Veterinary Antimicrobial Resistance Monitoring System (JVARM) and local public health institutes release information on resistance rates among animal- and food-derived pathogenic bacteria (resistant bacteria as a proportion of all identified bacteria). The AMR One Health Surveillance Committee summarizes these data (Nippon AMR One Health Report 2017: Environmental AMR surveillance, which deals mainly with rivers and sewage, was initiated by a research group and has been funded by a Health and Labour Sciences Research Grant (HLSRG) since 2018 (see p. 29 of this issue). National Action Plan and Performance Indicators The Global Action Plan (GAP) for AMR was adopted at the 2015 World Health Assembly (WHO), and in 2016, Japan drew up its own AMR National Action Plan (NAP) In response to the NAP, a wide variety of domestic and overseas AMR-related data are collected, and in order to feedback the information to the clinical settings, utilize the information for research, and provide policy guidance to WHO and other stakeholders, the AMR Research Center was established in 2017 in NIID to function as a comprehensive think-tank for AMR. The resistance rates for human-derived pathogenic bacteria, which is used as a performance indicator by NAP, is calculated based on JANIS data managed by the AMR Research Center in NIID. A resistance rate of 0.2% against carbapenem (imipenem and meropenem) for E. coli and K. pneumoniae is established as the performance indicator by NAP. In 2017, a meropenem resistance rate of 0.4% was found in K. pneumoniae, which was higher than the performance indicator, and the number of patients notified under the NESID system also increased in Therefore, in order to ascertain the epidemiological situation in each region of Japan and strengthen the ability to respond, continued implementation of national surveillance is necessary. The statistics in this report are based on 1) the data concerning patients and laboratory findings obtained by the National Epidemiological Surveillance of Infectious Diseases undertaken in compliance with the Act on the Prevention of Infectious Diseases and Medical Care for Patients with Infectious Diseases, and 2) other data covering various aspects of infectious diseases. The prefectural and municipal health centers and public health institutes (PHIs), the Department of Environmental Health and Food Safety, the Ministry of Health, Labour and Welfare, and quarantine stations, have provided the above data. Infectious Disease Surveillance Center, National Institute of Infectious Diseases Toyama , Shinjuku-ku, Tokyo , JAPAN Tel (+81-3)

CHEMOTHERAPY aureus 0.10, Enterococcus faecalis 3.13, Escherichia coli 0.20, Klebsiella pneumoniae, Enterobacter spp., Serratia marcescens 0.78, Prote

CHEMOTHERAPY aureus 0.10, Enterococcus faecalis 3.13, Escherichia coli 0.20, Klebsiella pneumoniae, Enterobacter spp., Serratia marcescens 0.78, Prote aureus 0.10, Enterococcus faecalis 3.13, Escherichia coli 0.20, Klebsiella pneumoniae, Enterobacter spp., Serratia marcescens 0.78, Proteus mirabilis 3.13, Proteus vulgaris 1.56, Citrobacter freundii 0.39,

More information

Fig. 1 Trends of TB incidence rates for all forms and smear-positive pulmonary TB in Kawasaki City and Japan. Incidence=newly notified cases of all fo

Fig. 1 Trends of TB incidence rates for all forms and smear-positive pulmonary TB in Kawasaki City and Japan. Incidence=newly notified cases of all fo Kekkaku Vol. 79, No. 1: 17-24, 2004 17 (Received 21 Aug. 2003/Accepted 18 Nov. 2003) Fig. 1 Trends of TB incidence rates for all forms and smear-positive pulmonary TB in Kawasaki City and Japan. Incidence=newly

More information

Fig. 1 Chemical structure of DL-8280

Fig. 1 Chemical structure of DL-8280 Fig. 1 Chemical structure of DL-8280 Fig. 2 Susceptibility of cl in ical isolates to DL4280 Fig. 5 Susceptibility of clinical isolates to DL-8280 Fig. 3 Susceptibility of clinical isolates to DL-8280 Fig.

More information

Key words : R-plasmid, Urinary tract infection, E. coli Fig. 1. MIC distribution against E. coli isolated from urinary tract (366 strains) and isolation - frequencies of drug-resistant strains Table 1.

More information

ñ{ï 01-65

ñ{ï 01-65 191252005.2 19 *1 *2 *3 19562000 45 10 10 Abstract A review of annual change in leading rice varieties for the 45 years between 1956 and 2000 in Japan yielded 10 leading varieties of non-glutinous lowland

More information

Table 1. Antibacterial activitiy of grepafloxacin and other antibiotics against clinical isolates

Table 1. Antibacterial activitiy of grepafloxacin and other antibiotics against clinical isolates Table 1. Antibacterial activitiy of grepafloxacin and other antibiotics against clinical isolates Table 2-1. Summary of patients treated with grepafloxacin for respiratory infection 1) Out: outpatient,

More information

CHEMOTHERAPY JUN Citrobacter freundii 27, Enterobacter aerogenes 26, Enterobacter cloacae 27, Proteus rettgeri 7, Proteus inconstans 20, Proteus

CHEMOTHERAPY JUN Citrobacter freundii 27, Enterobacter aerogenes 26, Enterobacter cloacae 27, Proteus rettgeri 7, Proteus inconstans 20, Proteus VOL. 32 S-4 CHEMOTHERAPY Fig. 1 Chemical structure of sodium cefoperazone Fig. 2 Chemical structure of sodium cefoperazone CHEMOTHERAPY JUN. 1984 Citrobacter freundii 27, Enterobacter aerogenes 26, Enterobacter

More information

CHEMOTHERAPY Proteus mirabilis GN-79 Escherichia coli No. 35 Proteus vulgaris GN-76 Pseudomonas aeruginosa No. 11 Escherichia coli ML-1410 RGN-823 Kle

CHEMOTHERAPY Proteus mirabilis GN-79 Escherichia coli No. 35 Proteus vulgaris GN-76 Pseudomonas aeruginosa No. 11 Escherichia coli ML-1410 RGN-823 Kle VOL. 29 NO.8 CHEMOTHERAPY 865 CHEMOTHERAPY Proteus mirabilis GN-79 Escherichia coli No. 35 Proteus vulgaris GN-76 Pseudomonas aeruginosa No. 11 Escherichia coli ML-1410 RGN-823 Klebsiella pneumoniae GN-69

More information

Table 1. Antibacterial spectrum SBT ABPC ABPC CPZ : sulbactamiampicillin : ampicillin : cefoperazone

Table 1. Antibacterial spectrum SBT ABPC ABPC CPZ : sulbactamiampicillin : ampicillin : cefoperazone Table 1. Antibacterial spectrum SBT ABPC ABPC CPZ : sulbactamiampicillin : ampicillin : cefoperazone (inoculum size= 106 CFU/ml) (Ĉ-lactamase producer : 2 strains) Fig. 1. Sensitivity distribution of

More information

1) i) Barber, M. et al.: Brit. Med J, 2, 565, 19'49. ii) Barber, M.F.G. J. Hayhoe and J. E. M. Whithead: Lancet, 1120 `1125, 1949.-2) Bergey: Bergey's Manual of Determinative Bacteriology 7 th Ed: (1958).-3)

More information

Table 1 Sensitivity distribution of clinical isolates 1. Escherichia coli Inoculum size: 106cells/ml 2. Klebsiella pneumoniae 3. Enterobacter cloacae 4. Serratia marcescens Inoculum size: 106cells/nil

More information

CHEMOTHERAPY JUNE 1993 Table 1. Background of patients in pharmacokinetic study

CHEMOTHERAPY JUNE 1993 Table 1. Background of patients in pharmacokinetic study CHEMOTHERAPY JUNE 1993 Table 1. Background of patients in pharmacokinetic study VOL. 41 S 1 Table 2. Levels (Đg/ml or Đg/g) of S-1006 in serum, bile, and tissue (gallbladder) after oral administration

More information

1272 CHEMOTHERAPY MAR. 1975

1272 CHEMOTHERAPY MAR. 1975 1272 CHEMOTHERAPY MAR. 1975 VOL. 23 NO. 3 CHEMOTHERAPY 1273 Fig. 2 Minimal inhibitory concentration of aminoglycosides against 50 strains of Klebsiella Fig. 1 Minimal inhibitory concentration of aminoglycosides

More information

CHEMOTHERAPY

CHEMOTHERAPY CHEMOTHERAPY VOL.41 S-2 Laboratory and clinical evaluation of teicoplanin CHEMOTHERAPY AUG. 1993 VOL.41 S-2 Laboratory and clinical evaluation of teicoplanin Table 1. Comparative in vitro activity of teicoplanin

More information

VOL.48 NO.7 lase negative staphylococci, Escherichia coli, Klebsiella spp., Citrobacter freundii, Enterobacter spp., indole-positive Proteus, Serratia

VOL.48 NO.7 lase negative staphylococci, Escherichia coli, Klebsiella spp., Citrobacter freundii, Enterobacter spp., indole-positive Proteus, Serratia ceftazidime, cefpirome, cefepime, cefoperazone/sulbactam (2: 1), imipenem Staphylococcus aureus oxacillin coagulase negative staphylococci Escherichia coli piperacillin Klebsiellac spp. Citrobacter Pseudomonas

More information

_念3)医療2009_夏.indd

_念3)医療2009_夏.indd Evaluation of the Social Benefits of the Regional Medical System Based on Land Price Information -A Hedonic Valuation of the Sense of Relief Provided by Health Care Facilities- Takuma Sugahara Ph.D. Abstract

More information

THE JAPANESE JOURNAL OF ANTIBIOTICS 48-8 Enterococcus avium 5Š, Corynebacterium xerosis 10Š, Corynebacterium pseudodiphtheriticum 10Š, Corynebacterium

THE JAPANESE JOURNAL OF ANTIBIOTICS 48-8 Enterococcus avium 5Š, Corynebacterium xerosis 10Š, Corynebacterium pseudodiphtheriticum 10Š, Corynebacterium THE JAPANESE JOURNAL OF ANTIBIOTICS 48-8 Enterobacter spp., Serratia spp., Burkholderia cepacia, Flavobacterium spp., Alcaligenes spp. THE JAPANESE JOURNAL OF ANTIBIOTICS 48-8 Enterococcus avium 5Š, Corynebacterium

More information

CHEMOTHERAPY

CHEMOTHERAPY CHEMOTHERAPY CHEMOTHERAPY Table 1 Antibacterial activity of BRL 28500 against standard strains of bacteria Fig, 1 Sensitivity distribution of ABPC-resistant E. coli isolated from urinary tract Fig. 2 Sensitivity

More information

CHEMOTHERAPY FEB Table 1. Activity of cefpirome and others against clinical isolates

CHEMOTHERAPY FEB Table 1. Activity of cefpirome and others against clinical isolates VOL.39 S-1 CHEMOTHERAPY FEB. 1981 Table 1. Activity of cefpirome and others against clinical isolates VOL.39 S-1 CHEMOTHERAPY FEB. 1991 72 M, 55.5 kg 66 F, 53 kg Chronic bronchitis Bronchopneumonia Peak

More information

b) Gram-negative bacteria Fig. 2 Sensitivity distribution of clinical isolates : E. coli Fig. 3 Sensitivity distribution of clinical isolates : Pseudomonas Fig. 1 Sensitivity distribution of clinical isolates

More information

VOL.32 S-7 CHEMOTHERAPY Table 1 MIC of standard strains of CTRX Fig. 2 Cumulative curves of MIC S. aureus (26 strains )

VOL.32 S-7 CHEMOTHERAPY Table 1 MIC of standard strains of CTRX Fig. 2 Cumulative curves of MIC S. aureus (26 strains ) CHEMOTHERAPY OCT. 1984 Fig. I Chemical structure of CTRX VOL.32 S-7 CHEMOTHERAPY Table 1 MIC of standard strains of CTRX Fig. 2 Cumulative curves of MIC S. aureus (26 strains ) CHEMOTHERAPY Fig. 3 Cumulative

More information

Staphylococcus sp. K.pneumoniae P.mirabilis C.freundii E. cloacae Serratia sp. P. aeruginosa ml, Enterococcus avium >100ƒÊg/ml

Staphylococcus sp. K.pneumoniae P.mirabilis C.freundii E. cloacae Serratia sp. P. aeruginosa ml, Enterococcus avium >100ƒÊg/ml CHEMOTHERAPY SEPT. 1992 cefoperazone ceftazidime (CAZ), imipenem (IPM) Staphylococcus sp., Enterococcus (CPZ), faecalis, Escherichia coli, Klebsiella pneumoniae, Citrobacter freundii, Enterobacter cloacae,

More information

<95DB8C9288E397C389C88A E696E6462>

<95DB8C9288E397C389C88A E696E6462> 2011 Vol.60 No.2 p.138 147 Performance of the Japanese long-term care benefit: An International comparison based on OECD health data Mie MORIKAWA[1] Takako TSUTSUI[2] [1]National Institute of Public Health,

More information

epidermidis, Enterococcus faecalis, Enterococcus Klebsiella pneumoniae, Proteus mirabilis, indolepositive Proteus spp., Enterobacter spp., Serratia

epidermidis, Enterococcus faecalis, Enterococcus Klebsiella pneumoniae, Proteus mirabilis, indolepositive Proteus spp., Enterobacter spp., Serratia epidermidis, Enterococcus faecalis, Enterococcus Klebsiella pneumoniae, Proteus mirabilis, indolepositive Proteus spp., Enterobacter spp., Serratia Table 3. Overall clinical efficacy of cefozopran in

More information

400 46 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 Dec. 2012 LVFX 100 mg 3 / 7 150 mg 2 / 7 2 2006 2008 9 LVFX PK PD 2009 7 100 mg 1 3 500 mg 1 1 AUC/MIC

400 46 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 Dec. 2012 LVFX 100 mg 3 / 7 150 mg 2 / 7 2 2006 2008 9 LVFX PK PD 2009 7 100 mg 1 3 500 mg 1 1 AUC/MIC Dec. 2012 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 399 45 2012 11 5 LVFX 500 mg 1 1 20 Chlamydia trachomatis C. trachomatismycoplasma genitalium M. genitalium LVFX 1 500 mg 1 1 7 22 22 C. trachomatis 17

More information

ON A FEW INFLUENCES OF THE DENTAL CARIES IN THE ELEMENTARY SCHOOL PUPIL BY Teruko KASAKURA, Naonobu IWAI, Sachio TAKADA Department of Hygiene, Nippon Dental College (Director: Prof. T. Niwa) The relationship

More information

VOL.35 S-2 CHEMOTHERAPY Table 1 Sex and age distribution Table 2 Applications of treatment with carumonam Table 3 Concentration of carumonam in human

VOL.35 S-2 CHEMOTHERAPY Table 1 Sex and age distribution Table 2 Applications of treatment with carumonam Table 3 Concentration of carumonam in human CHEMOTHERAPY Fig. 1 Chemical structure of carumonam Disodium(+)-(Z)-CCE1-(2-amino-4-thiazoly1)-2-[[(2S, -(carbamoyloxymethyl)-4-oxo-1-sulfonato-3-azetidinyll -2-oxoethylidene] amino] oxy] acetate 3S)-2

More information

Yamagata Journal of Health Sciences, Vol. 16, 2013 Tamio KEITOKU 1 2 Katsuko TANNO 3 Kiyoko ARIMA 4 Noboru CHIBA 1 Abstract The present study aimed to

Yamagata Journal of Health Sciences, Vol. 16, 2013 Tamio KEITOKU 1 2 Katsuko TANNO 3 Kiyoko ARIMA 4 Noboru CHIBA 1 Abstract The present study aimed to Yamagata Journal of Health Sciences, Vol. 16, 2013 Tamio KEITOKU 12Katsuko TANNO 3Kiyoko ARIMA 4Noboru CHIBA 1 Abstract The present study aimed to clarify differences in awareness regarding future residence

More information

coccus aureus Corynebacterium sp, Haemophilus parainfluenzae Klebsiella pneumoniae Pseudornonas aeruginosa Pseudomonas sp., Xanthomonas maltophilia, F

coccus aureus Corynebacterium sp, Haemophilus parainfluenzae Klebsiella pneumoniae Pseudornonas aeruginosa Pseudomonas sp., Xanthomonas maltophilia, F VOL.43 S-1 coccus aureus Corynebacterium sp, Haemophilus parainfluenzae Klebsiella pneumoniae Pseudornonas aeruginosa Pseudomonas sp., Xanthomonas maltophilia, Flavobacter- Table 1. Concentration of grepafloxacin

More information

Table 1.Resistance criteria Fig.1.The resistance rates of piperacillin,ceftazidime, cefsulodin,imipenem,aztreonam,gentamicin,tobramycin,amikacin,isepamicin,fosfomycin and ofloxacin against 2,793 strains

More information

日本化学療法学会雑誌第61巻第6号

日本化学療法学会雑誌第61巻第6号 β Moraxella catarrhalis Escherichia coli Citrobacter Klebsiella pneumoniae Enterobacter cloacae Serratia marcescens Proteus Pseudomonas aeruginosa Acinetobacter Bacteroides fragilis β Haemophilus influenzae

More information

CHEMOTHERAPY APRIL 1992 Table 2. Concentration of meropenem in human prostatic fluid Table 1. Background of 21 chronic complicated UTI cases * NB + BPH, NB + Kidney tumor, NB + Kidney tuberculosis Table

More information

VOL. 40 S- 1 Table 1. Susceptibility of methicillin-resistant Staphylococcus aureus to meropenem Table 2. Coagulase typing of methicillin-resistant St

VOL. 40 S- 1 Table 1. Susceptibility of methicillin-resistant Staphylococcus aureus to meropenem Table 2. Coagulase typing of methicillin-resistant St CHEMOTHERAPY VOL. 40 S- 1 Table 1. Susceptibility of methicillin-resistant Staphylococcus aureus to meropenem Table 2. Coagulase typing of methicillin-resistant Staphylococcus aureus CHEMOTHERAPY Table

More information

Abstract Objectives: This article presents a review of cancer control measures implemented in Phase One of the National Cancer Control Plan (

Abstract Objectives: This article presents a review of cancer control measures implemented in Phase One of the National Cancer Control Plan ( 2012Vol.61No.6p.524542 The Japanese National Cancer Control Plan: A Review of Phase One and lessons learned for Phase Two Ken-ichi HANIOKA Cancer Policy Information Center, Health and Global Policy Institute

More information

日本化学療法学会雑誌第64巻第4号

日本化学療法学会雑誌第64巻第4号 β β Moraxella catarrhalisescherichia colicitrobacter Klebsiella pneumoniaeenterobacter cloacaeserratia marcescens Proteus Providencia Pseudomonas aeruginosaacinetobacter Bacteroides fragilis β β E. colik.

More information

Oct THE JAPANESE JOURNAL OF ANTIBIOTICS Pseudomonas aeruginosa 186 P. aeruginosa piperacillin PIPC, taz

Oct THE JAPANESE JOURNAL OF ANTIBIOTICS Pseudomonas aeruginosa 186 P. aeruginosa piperacillin PIPC, taz Oct. 2016 THE JAPANESE JOURNAL OF ANTIBIOTICS 69 5 327 27 2013 2014 2016 7 5 2013 2014 Pseudomonas aeruginosa 186 P. aeruginosa piperacillin PIPC, tazobactam/piperacillin TAZ/PIPC, ceftazidime CAZ, cefepime

More information

840 Geographical Review of Japan 73A-12 835-854 2000 The Mechanism of Household Reproduction in the Fishing Community on Oro Island Masakazu YAMAUCHI (Graduate Student, Tokyo University) This

More information

Table 1 Survival rates of infected mice given antibiotic doses producing peak serum a) S. aurcus Smith Challenge dose :7 ~10 (5% mucin) CFU/mouse. LD50: 1 ~103 (5% mucin) CFU/mouse. Table 2 Survival rates

More information

ABSTRACT The movement to increase the adult literacy rate in Nepal has been growing since democratization in 1990. In recent years, about 300,000 peop

ABSTRACT The movement to increase the adult literacy rate in Nepal has been growing since democratization in 1990. In recent years, about 300,000 peop Case Study Adult Literacy Education as an Entry Point for Community Empowerment The Evolution of Self-Help Group Activities in Rural Nepal Chizu SATO Masamine JIMBA, MD, PhD, MPH Izumi MURAKAMI, MPH Massachusetts

More information

VOL. 23 NO. 3 CHEMOTHERAPY 1067 Table 2 Sensitivity of gram positive cocci isolated from various diagnostic materials Table 3 Sensitivity of gram nega

VOL. 23 NO. 3 CHEMOTHERAPY 1067 Table 2 Sensitivity of gram positive cocci isolated from various diagnostic materials Table 3 Sensitivity of gram nega 1066 CHEMOTHERAPY MAR. 1975 Table 1 Sensitivity of standard strains VOL. 23 NO. 3 CHEMOTHERAPY 1067 Table 2 Sensitivity of gram positive cocci isolated from various diagnostic materials Table 3 Sensitivity

More information

Fig.2. Sensitivity distribution of clinical isolates of S. epidermidis (24 strains, 106 CFU/ml) Staphylococcus aureus Staphylococcus epider- midis Ent

Fig.2. Sensitivity distribution of clinical isolates of S. epidermidis (24 strains, 106 CFU/ml) Staphylococcus aureus Staphylococcus epider- midis Ent Fig.2. Sensitivity distribution of clinical isolates of S. epidermidis (24 strains, 106 CFU/ml) Staphylococcus aureus Staphylococcus epider- midis Enterococcus faecalis Klebsiella pneumoniae, Morganella

More information

366 12 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 Dec. 2012 1 8 DNA 2,3 16 12 20 171 2008 12 2010 11 2 3,558 4.44% 1.65% 1.17% 90% 9 Escherichia coli -

366 12 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 Dec. 2012 1 8 DNA 2,3 16 12 20 171 2008 12 2010 11 2 3,558 4.44% 1.65% 1.17% 90% 9 Escherichia coli - Dec. 2012 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 365 11 sita oxacin 1 1 1 1 1 1 2 2 3 3 1 1 1 2 3 2012 9 14 sita oxacin STFX 50 mg 10% 2008 1 2008 12 2010 11 2 STFX 1,452 91.4% 1,235/1,351 95.9% 466/486

More information

Oda

Oda No.53 pp.2334, 2017 Komazawa Journal of Geography Distribution of Christianity and the Division of the Region in Prewar Japan ODA Masayasu Oda1999 1. 18991939 1 2. 18991939 1918 3. 190019391939 4. 5. 6.

More information

CHEMOTHERAPY Table 1 Clinical effect of Sultamicillin

CHEMOTHERAPY Table 1 Clinical effect of Sultamicillin CHEMOTHERAPY CHEMOTHERAPY Table 1 Clinical effect of Sultamicillin CHEMOTHERAPY Fig. 1 MICs of sultamicillin against respiratory pathogenic Branhamella catarrhalis 62 strains, inoculum size 106CFU/m1 Fig.

More information

untitled

untitled Infectious Agents Surveillance Report (IASR) http://www.nih.go.jp/niid/ja/iasr.html 3, CRE 4, CRE 5, CRE 7, CRE 8, CRE 9, CRE 10, 11, 1 13, EHEC O121 : 14, D-68 4 : 15, 2014 : 16, 10 A : 18, 2 1 20 Vol.

More information

2 10 The Bulletin of Meiji University of Integrative Medicine 1,2 II 1 Web PubMed elbow pain baseball elbow little leaguer s elbow acupun

2 10 The Bulletin of Meiji University of Integrative Medicine 1,2 II 1 Web PubMed elbow pain baseball elbow little leaguer s elbow acupun 10 1-14 2014 1 2 3 4 2 1 2 3 4 Web PubMed elbow pain baseball elbow little leaguer s elbow acupuncture electric acupuncture 2003 2012 10 39 32 Web PubMed Key words growth stage elbow pain baseball elbow

More information

Table 1 Antibacterial spectra of CPM and other antimicrobials against anaerobes Fig. 1 In vitro activity of CPM and other antibiotics against B. fragilis (136 strains) Fig. 2 In vitro activity of CPM and

More information

Key words: Antibodies to Leptospira, Tokyo, Uveitis

Key words: Antibodies to Leptospira, Tokyo, Uveitis Key words: Antibodies to Leptospira, Tokyo, Uveitis Fig. 1 Distribution of Antibody Titers in Age Decade Fig. 3 Distribution of Antibody Titers in each Strain Fig. 2 Correlation between Antibody Titers

More information

The Journal of the Japan Academy of Nursing Administration and Policies Vol 7, No 2, pp 19 _ 30, 2004 Survey on Counseling Services Performed by Nursi

The Journal of the Japan Academy of Nursing Administration and Policies Vol 7, No 2, pp 19 _ 30, 2004 Survey on Counseling Services Performed by Nursi The Journal of the Japan Academy of Nursing Administration and Policies Vol 7, No 2, pp 19 _ 30, 2004 Survey on Counseling Services Performed by Nursing Professionals for Diabetic Outpatients Not Using

More information

在日外国人高齢者福祉給付金制度の創設とその課題

在日外国人高齢者福祉給付金制度の創設とその課題 Establishment and Challenges of the Welfare Benefits System for Elderly Foreign Residents In the Case of Higashihiroshima City Naoe KAWAMOTO Graduate School of Integrated Arts and Sciences, Hiroshima University

More information

Title 社 会 化 教 育 における 公 民 的 資 質 : 法 教 育 における 憲 法 的 価 値 原 理 ( fulltext ) Author(s) 中 平, 一 義 Citation 学 校 教 育 学 研 究 論 集 (21): 113-126 Issue Date 2010-03 URL http://hdl.handle.net/2309/107543 Publisher 東 京

More information

Table1MIC of BAY o 9867 against standard strains

Table1MIC of BAY o 9867 against standard strains Table1MIC of BAY o 9867 against standard strains Fig.2Cumulative and Distribution Curves of MIC (S.aureus 54 strains) 106cfu/ml Fig.3Correlogram of MIC (S.aureus 54 strains) CHEMOTHERAPY 451 Fig.4Cumulative

More information

Fig. 1 Chemical structure of TE-031 Code number: TE-031 Chemical name: (-) (3R, 4S, 5S, 6R, 7R, 9R, 11R, 12R, 13S, 14R)-4-[(2, 6-dideoxy-3-C-methyl-3-

Fig. 1 Chemical structure of TE-031 Code number: TE-031 Chemical name: (-) (3R, 4S, 5S, 6R, 7R, 9R, 11R, 12R, 13S, 14R)-4-[(2, 6-dideoxy-3-C-methyl-3- Fig. 1 Chemical structure of TE-031 Code number: TE-031 Chemical name: (-) (3R, 4S, 5S, 6R, 7R, 9R, 11R, 12R, 13S, 14R)-4-[(2, 6-dideoxy-3-C-methyl-3-O-methyl-a-L-ribo-hexopyranosyl) oxy]-14-ethyl-12,

More information

Fig.1 Chemical structure of BAY o 9867

Fig.1 Chemical structure of BAY o 9867 Fig.1 Chemical structure of BAY o 9867 CHEMOTHERAPY 43 Table 3 Antibacterial spectrum of gram negative bacteria Medium:Heart infusion agar (Nissui) Method:Agar dilution (Streak) CHEMOTHERAPY DEC 1985

More information

Fig. 1 Clinical findings and extent of inflammation area in female urethrocystitis Fig. 2 Classification and distribution of female patients with blad

Fig. 1 Clinical findings and extent of inflammation area in female urethrocystitis Fig. 2 Classification and distribution of female patients with blad Key words: Female with bladder irritability, Subjective symptoms, Pyuria, Bacteriuria Fig. 1 Clinical findings and extent of inflammation area in female urethrocystitis Fig. 2 Classification and distribution

More information

特殊病態下感染症における抗菌薬治験の手引き作成委員会報告書(案)

特殊病態下感染症における抗菌薬治験の手引き作成委員会報告書(案) VOL.51 NO.6 JUNE 2003 JUNE 2003 9) Niederman MS et al: Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy and prevention.

More information

2 The Bulletin of Meiji University of Integrative Medicine 3, Yamashita 10 11

2 The Bulletin of Meiji University of Integrative Medicine 3, Yamashita 10 11 1-122013 1 2 1 2 20 2,000 2009 12 1 2 1,362 68.1 2009 1 1 9.5 1 2.2 3.6 0.82.9 1.0 0.2 2 4 3 1 2 4 3 Key words acupuncture and moxibustion Treatment with acupuncture, moxibustion and Anma-Massage-Shiatsu

More information

Influences of mortality from main causes of death on life expectancy. \ An observation for the past 25 years, 1950-1975, in Japan \ Takao SHIGEMATSU* and Zenji NANJO** With the Keyfitz-Nanjo method an

More information

千葉県における温泉地の地域的展開

千葉県における温泉地の地域的展開 1) 1999 11 50 1948 23) 2 2519 9 3) 2006 4) 151 47 37 1.2 l 40 3.6 15 240 21 9.2 l 7. 210 1972 5) 1.9 l 5 1 0.2 l 6 1 1972 1.9 0.4 210 40-17- 292006 34 6 l/min.42 6) 2006 1 1 2006 42 60% 5060 4050 3040

More information

/fiÁ1-1/‹Éfi¡ıæ„[’æ’¶

/fiÁ1-1/‹Éfi¡ıæ„[’æ’¶ 59 1 pp.53-58 2009 1. H5N1 3 H5N1 2007 1 2 2008 4 5 2003 H5N1 2005 50 1 429 262 2009 5 22 2 680-8553 4 101 TEL/FAX : 0857-31-5437 E-mail: toshiito@muses.tottori-u.ac.jp 3 H5N1 1 A A A 54 59 1 4 A A 5 1997

More information

J. Jpn. Acad. Nurs. Sci., Vol.25, No.1, pp.13-22, 2005 Decision Making under the Uncertainty; Process of Decision from Diagnosis to Preventive- Operat

J. Jpn. Acad. Nurs. Sci., Vol.25, No.1, pp.13-22, 2005 Decision Making under the Uncertainty; Process of Decision from Diagnosis to Preventive- Operat J. Jpn. Acad. Nurs. Sci., Vol.25, No.1, pp.13-22, 2005 Decision Making under the Uncertainty; Process of Decision from Diagnosis to Preventive- Operation in Patient with Asymptomatic Cerebrovascular Diseases

More information

大学論集第42号本文.indb

大学論集第42号本文.indb 42 2010 2011 3 279 295 COSO 281 COSO 1990 1 internal control 1 19962007, Internal Control Integrated Framework COSO COSO 282 42 2 2) the Committee of Sponsoring Organizations of the Treadway committee

More information

CHEMOTHERAPY APRIL 1992 VOL. 40 S- 1 Table 1-1. Comparative in vitro activity of meropenem against clinical isolates CNS: coagulase-negative staphylococci CHEMOTHERAPY APRIL 1992 Table 1-2. Comparative

More information

49148

49148 Research in Higher Education - Daigaku Ronshu No.24 (March 1995) 77 A Study of the Process of Establishing the Student Stipend System in the Early Years of the PRC Yutaka Otsuka* This paper aims at explicating

More information

,

, , The Big Change of Life Insurance Companies in Japan Hisayoshi TAKEDA Although the most important role of the life insurance system is to secure economic life of the insureds and their

More information

CHEMOTHERAPY Table 1 Urinary excretion of mezlocillin Fig. 4 Urinary excretion of mezlocillin Fig. 3 Blood levels of mezlocillin

CHEMOTHERAPY Table 1 Urinary excretion of mezlocillin Fig. 4 Urinary excretion of mezlocillin Fig. 3 Blood levels of mezlocillin CHEMOTHERAPY Fig. 2 Urinary excretion of mezlocillin Fig. 1 Blood levels of mezlocillin CHEMOTHERAPY Table 1 Urinary excretion of mezlocillin Fig. 4 Urinary excretion of mezlocillin Fig. 3 Blood levels

More information

VOL.47 NO.5 Table 1. Susceptibility distribution of Ĉ- lactams against clinical isolates of MRSA MRSA: rnethicillin- resistant Staphylococcus aureus

VOL.47 NO.5 Table 1. Susceptibility distribution of ƒà- lactams against clinical isolates of MRSA MRSA: rnethicillin- resistant Staphylococcus aureus MAY 1999 VOL.47 NO.5 Table 1. Susceptibility distribution of ƒà- lactams against clinical isolates of MRSA MRSA: rnethicillin- resistant Staphylococcus aureus (oxacillin MIC: 4ƒÊg/ ml) FMOX: flomoxef,

More information

THE JAPANESE JOURNAL OF ANTIBIOTICS 68 3 June 2015 Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis % 2 S. pneumon

THE JAPANESE JOURNAL OF ANTIBIOTICS 68 3 June 2015 Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis % 2 S. pneumon June 2015 THE JAPANESE JOURNAL OF ANTIBIOTICS 68 3 189 49 1 : 14 1 2 2 3 1 2 3 2015 4 3 1 : 14 CVA/AMPC 1 : 14 27 CVA/AMPC 1 : 14 88.5% Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis

More information

The Effect of the Circumferential Temperature Change on the Change in the Strain Energy of Carbon Steel during the Rotatory Bending Fatigue Test by Ch

The Effect of the Circumferential Temperature Change on the Change in the Strain Energy of Carbon Steel during the Rotatory Bending Fatigue Test by Ch The Effect of the Circumferential Temperature Change on the Change in the Strain Energy of Carbon Steel during the Rotatory Bending Fatigue Test by Chikara MINAMISAWA, Nozomu AOKI (Department of Mechanical

More information

Key words: bacterial meningitis, Haemophilus influenzae type b, Streptococcus pneumoniae, rapid diagnosis, childhood

Key words: bacterial meningitis, Haemophilus influenzae type b, Streptococcus pneumoniae, rapid diagnosis, childhood Key words: bacterial meningitis, Haemophilus influenzae type b, Streptococcus pneumoniae, rapid diagnosis, childhood Fig.1 Distribution of the cases with bacterial meningitis by age and pathogens Chiba

More information

A comparison of abdominal versus vaginal hysterectomy for leiomyoma and adenomyosis Kenji ARAHORI, Hisasi KATAYAMA, Suminori NIOKA Department of Obstetrics and Gnecology, National Maizuru Hospital,Kyoto,

More information

The Tohoku Medical Megabank project is a part of the national project to reconstruct Tohoku area.. It aims to become a centripetal force for the reconstruction of Tohoku University Tohoku Medical Megabank

More information

2) Goetz, A., Tsuneishi, N.: Application of molecular filter membranes to the bacteriological analysis of water, J. Am. Water Works Assn., 43 (12): 943-969,1951. 3) Clark, H.F. et al.: The membrane filter

More information

15) Egawa, R., Sawai, T. and Mit.uhashi, S.: Jap. J. Microbiol., 11 : 173-178, 1967. 16) Tanaka, T. and Hashimoto, H., Nagai, Y. and Mitsuhashi, S.: Jap. J. Microbiol., 11: 155-162, 1967. 17) Mitsuhashi,

More information

CHEMOTHERAPY NOV S. aureus, S. epidermidis, E. coli, K. pgeumoniae, E. cloacae, S. marcescens, P. mirabilis, Proteus, P. aeruginosa Inoculum siz

CHEMOTHERAPY NOV S. aureus, S. epidermidis, E. coli, K. pgeumoniae, E. cloacae, S. marcescens, P. mirabilis, Proteus, P. aeruginosa Inoculum siz VOL.33 S-5 CHEMOTHERAPY 381 Fig. 1 Chemical structure of HAPA-B Chemical name 1-N-[(2S)-3-Amino-2-hydroxypropiony1]-4-0-(6-amino- 6-deoxy-a-D-glucopyranosyl)-6-013-deoxy-4-C-methyl- 3-(methylamino)-ƒÀ-L-arabinopyranosyl]-2-deoxystreptamine

More information

Key words: E. coli O 157: H7, fosfomycin, verotoxin, mouse infection

Key words: E. coli O 157: H7, fosfomycin, verotoxin, mouse infection Key words: E. coli O 157: H7, fosfomycin, verotoxin, mouse infection Table 1. Bacterial cell counts in feces of mice infected with Esclwrichia coli O 157: H7 NK2 before and during oral dosing with fosfomycin

More information

Studies of Foot Form for Footwear Design (Part 9) : Characteristics of the Foot Form of Young and Elder Women Based on their Sizes of Ball Joint Girth

Studies of Foot Form for Footwear Design (Part 9) : Characteristics of the Foot Form of Young and Elder Women Based on their Sizes of Ball Joint Girth Studies of Foot Form for Footwear Design (Part 9) : Characteristics of the Foot Form of Young and Elder Women Based on their Sizes of Ball Joint Girth and Foot Breadth Akiko Yamamoto Fukuoka Women's University,

More information

CHEMOTHERAPY Fig. 1 Chemical structure of CXM-AX

CHEMOTHERAPY Fig. 1 Chemical structure of CXM-AX Fig. 1 Chemical structure of CXM-AX NOV. 1986 Fig. 2 Sensitivity distribution of clinical isolates organisms (106 cells/ml) a Smurcus 27 strains d) P.m irabilis 15 strains b Ecol i 27 strains 111.morganii

More information

16_.....E...._.I.v2006

16_.....E...._.I.v2006 55 1 18 Bull. Nara Univ. Educ., Vol. 55, No.1 (Cult. & Soc.), 2006 165 2002 * 18 Collaboration Between a School Athletic Club and a Community Sports Club A Case Study of SOLESTRELLA NARA 2002 Rie TAKAMURA

More information

11_渡辺_紀要_2007

11_渡辺_紀要_2007 56 1 19 Bull. Nara Univ. Educ., Vol. 56, No.1 (Cult. & Soc.), 2007 115 19 Why is Kidney Dysfunction Caused by Cadmium (Cadmium Nephropathy) not Officially Recognized as a Pollution-related Disease by the

More information

VOL.30 NO.12 CHEMOTHERAPY Fig. 1 Effect of temperature on the growth curve of A. calcoaceticus A. calcoaceticits Ac 54 A. calcoacetictts Ac 164 Fig. 2 Effect of medium ph on the growth curve of A. calcoaceticus

More information

44 2012 2013 3 35 48 法人化後の国立大学の収入変動 37 法人化後の国立大学の収入変動 2009 2005 2010 2012 2012 2008 2009a 2010 16 18 17 20 2 4 2012 38 44 2012 17 22 (1) (2) 2012 5 GP COE 30 WPI 1 2012 17 22 16 17 22 17 17 19 2012 2012

More information

E Societe de Pathologie Infectieuse de Langue Francaise (, 1991) E Spanish Thoracic Society (1992) E American Thoracic Society (ATS : 1993. ü ù2001 ) E British Thoracic Society (1993, ü è2001 ) E Canadian

More information

Title 泌尿器科領域に於ける17-Ketosteroidの研究 17-Ketosteroidの臨床的研究 第 III 篇 : 尿 Author(s) 卜部, 敏入 Citation 泌尿器科紀要 (1958), 4(1): 3-31 Issue Date URL

Title 泌尿器科領域に於ける17-Ketosteroidの研究 17-Ketosteroidの臨床的研究 第 III 篇 : 尿 Author(s) 卜部, 敏入 Citation 泌尿器科紀要 (1958), 4(1): 3-31 Issue Date URL Title 泌尿器科領域に於ける17-Ketosteroidの研究 17-Ketosteroidの臨床的研究 第 III 篇 : 尿 Author(s) 卜部, 敏入 Citation 泌尿器科紀要 (1958), 4(1): 3-31 Issue Date 1958-01 URL http://hdl.handle.net/2433/111559 Right Type Departmental Bulletin

More information

Ⅱ. 用語の操作的定義 Ⅲ. 対象と方法 1. 対象 WAM NET 2. 調査期間 : 3. 調査方法 4. 調査内容 5. 分析方法 FisherMann-Whitney U Kruskal-Wallis SPSS. for Windows 6. 倫理的配慮 Vol. No.

Ⅱ. 用語の操作的定義 Ⅲ. 対象と方法 1. 対象 WAM NET 2. 調査期間 : 3. 調査方法 4. 調査内容 5. 分析方法 FisherMann-Whitney U Kruskal-Wallis SPSS. for Windows 6. 倫理的配慮 Vol. No. 研究報告 The Relation Between the Manager s Administrative Abilities Including Business Activities in Visiting Nursing Stations and the Station s Financial Profits Chisato Fujii Akiko Akama Mariko Ohtake Ikuko

More information

) ,

) , Vol. 2, 1 17, 2013 1986 A study about the development of the basic policy in the field of reform of China s sports system 1986 HaoWen Wu Abstract: This study focuses on the development of the basic policy

More information

評論・社会科学 90号(よこ)(P)/4.咸

評論・社会科学 90号(よこ)(P)/4.咸 1 2008 7 1 1 4 5 1 1998 2003 2005 3 2 2008 7 1 2009 7 30 2009 11 18 2009 2009 2008 1 1 1 1 65 1970 3.1 2000 7.2 7 2008 10.7 14 2018 1 2 1985 41.92008 50.0 2004 15 59 2003 2010 79 2020 114 OECD 1 65 2006

More information

CHEMOTHERAPY

CHEMOTHERAPY CHEMOTHERAPY CHEMOTHERAPY Table 1 Antibacterial activity of Sulbactam/CPZ against standard strains MIC mg/ml Inoculum size 106 CFU/ml * Sulbactam/CPZ= 1: 1 ** Concentration of Sulbactam+ CPZ CHEMOTHERAPY

More information

CHEMOTHERAPY JUNE 1987 Table1 Media used *BHIB, brain heart infusion broth (Difco); /3 -NAD, S -nicotinamidoadeninedinucleotide (Sigma Chemical Co.);

CHEMOTHERAPY JUNE 1987 Table1 Media used *BHIB, brain heart infusion broth (Difco); /3 -NAD, S -nicotinamidoadeninedinucleotide (Sigma Chemical Co.); VOL.35 S-2 CHEMOTHERAPY Fig.1 Chemical structure of carumonam CHEMOTHERAPY JUNE 1987 Table1 Media used *BHIB, brain heart infusion broth (Difco); /3 -NAD, S -nicotinamidoadeninedinucleotide (Sigma Chemical

More information

Table 1 Distribution,by type and classroom,of group B hemolytic streptococcal strains isolated from throat of pupils in A elementary school in Nishime

Table 1 Distribution,by type and classroom,of group B hemolytic streptococcal strains isolated from throat of pupils in A elementary school in Nishime Key words: Group B hemolytic streptococci, Types, Elementary & Junior high school pupils, 7 prefectures Table 1 Distribution,by type and classroom,of group B hemolytic streptococcal strains isolated from

More information

YUHO

YUHO -1- -2- -3- -4- -5- -6- -7- -8- -9- -10- -11- -12- -13- -14- -15- -16- -17- -18- -19- -20- -21- -22- -23- -24- -25- -26- -27- -28- -29- -30- -31- -32- -33- -34- -35- -36- -37- -38- -39- -40- -41- -42-

More information

29 33 58 2005 1970 1997 2002, pp.3-8 2001 2002 2005b 2000 pp.137-146 2005c 7 34 Ma and Cartier eds. 2003 1970 1980 1979 2002 2000 1) 1980 1990 1991 1993 1995 1998 1994 1993 20031972 2003 2005 1997 2005a

More information

VOL.42 S-1

VOL.42 S-1 CHEMOTHERAPY APR. 1994 VOL.42 S-1 CHEMOTHERAPY APR. 1994 Table 1. Criteria for evaluation of clinical efficacy by the Japanese Society of Oral and Maxillo-Facial Surgeons Grades of symptoms and numerical

More information

untitled

untitled SATO Kentaro Milk and its by-products are naturally nutritious food, and people in ancient Japan enjoyed tasting them as foods, drinks, or medicines. On the other hand, milk and its by-products were closely

More information

Table 1 Profiles of 28 patients with Legionella pneumonia in Japan, 1980-1990 a) Y Taguchi, personal communication b) M. Hayase, personal communicatio

Table 1 Profiles of 28 patients with Legionella pneumonia in Japan, 1980-1990 a) Y Taguchi, personal communication b) M. Hayase, personal communicatio Key words: Legionella pneumonia, culture-positive, Japanese patients Legionella (L. pneumophila (L. micdadei, L. bozemanii, Table 1 Profiles of 28 patients with Legionella pneumonia in Japan, 1980-1990

More information

10-渡部芳栄.indd

10-渡部芳栄.indd COE GCOE GP ) b a b ) () ) () () ) ) .. () ) ) ) ) () ........... / / /.... 交付税額 / 経常費 : 右軸交付税額 /( 経常費 授業料 ): 右軸 . ) ()... /.. 自治体負担額 / 交付税額 : 右軸 ()......... / 自治体負担額 / 経常費 : 右軸 - No. - Vol. No. - IDE

More information

VOL. 43 NO. 4

VOL. 43 NO. 4 VOL. 43 NO. 4 Fig. 1. Frequency of Enterococcus species from complicated UTI, 1988-1992. the number * of Enterococcus species/the number of cases with complicated UTI. Fig. 3 Epidemiologic characteristics

More information

<30372D985F95B62D8E52967B8C4F8E7190E690B62E706466>

<30372D985F95B62D8E52967B8C4F8E7190E690B62E706466> 312013 95 Changes and Restructuring of Social Issues of the Urban Underclass Area with Increasing Welfare Needs in Kotobuki, Yokohama Kahoruko YAMAMOTO This paper explains social changes and restructuring

More information

(2001)(2001)(2001)(2001)(2001)

(2001)(2001)(2001)(2001)(2001) No.42 2007 pp.27 38 Redevelopment in Surrounding Railway Stations and Change of Urban Structure Mainly with Reutilization of the Sites where Factories were Located Yukio NAGANO Received September 30, 2006

More information

9 1, , , 2002, 1998, 1988,

9 1, , , 2002, 1998, 1988, J. Japan Soc. Hydrol. & Water Resour. Vol. 20, No.1, Jan. 2007 pp. 34-46 Dushmanta, Srikantha, 2004 "basin wide integrated flood management strategy" IV.2.50 9 1,893 333 3 528 109 54, 1987 50 9, 2002,

More information